Effect of Leish G1 cream in leishmaniasis

Evaluation Leish G1 cream efficacy on healing the cutaneous leishmaniasis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180115038383N1

Enrollment

100

Registered

2018-02-08

Start date

2018-02-04

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention group: Topical use of Leish G1 cream on leishmanial lesions twice daily for two months. The medication is a formulation of aquas garlic extract based on Eucerin, formulate

Eligibility

Sex/Gender

All

Age

12 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with Cutaneous leishmaniasis approved by direct examinations Up to 5 lesions in each patient Duration of disease up to 3 months Patients who have not used anti leishmaniasis therapies

Exclusion criteria

Exclusion criteria: Patients with facial lesions Patients with Lymphangitis lesions Patients with Immunodeficiency disorders Patients who use immunosuppressive drugs Patients with other skin diseases such as Eczema, Psoriasis and Lupus Patients with severe mental disorders such as Major Depressive Disorder and Psychosis Concomitant use of other medications Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Wound healing. Timepoint: Evaluating size and grade of cutaneous lesion in days 0, 14, 28 and 60 aftertreatment. Method of measurement: Ruler.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Emadi

Shahed University

f.emadi@shahed.ac.ir+98 21 6646 4320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026